Sugi Predict

Sugi Predict / Compounds / SCHEMBL318947

SCHEMBL318947

SCHEMBL318947

O=C1Nc2ccccc2C1(F)F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDK2 Q15119 1/20 0.57
▸ PDK4 Q16654 1/20 0.57
▸ LMNA P02545 2/20 0.53
▸ KMT2A Q03164 4/20 0.48
▸ MEN1 O00255 3/20 0.48
▸ ALDH1A1 P00352 5/20 0.47
▸ GAA P10253 4/20 0.47
▸ POLB P06746 1/20 0.47
▸ CHRM2 P08172 1/20 0.47
▸ ADORA3 P0DMS8 1/20 0.47
▸ KCNH2 Q12809 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ AKR1B1 P15121 1/20 0.47
▸ KDM4E B2RXH2 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ BACE1 P56817 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ RUNX1 Q01196 1/20 0.46
▸ CBFB Q13951 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29651321 1.00 PDK2 (0.57) PDK2PDK4LMNAKMT2AMEN1
SCHEMBL29237808 0.78 PDK2 (0.53) PDK2PDK4LMNAKMT2AMEN1
SCHEMBL2264508 0.78 PDK2 (0.64) PDK2PDK4LMNAKMT2AMEN1
SCHEMBL2264504 0.78 PDK2 (0.64) PDK2PDK4LMNAKMT2AMEN1
SCHEMBL2266448 0.78 PDK2 (0.64) PDK2PDK4LMNAKMT2AMEN1
SCHEMBL25340217 0.76 LMNA (0.76) PDK2PDK4LMNAKMT2AMEN1
SCHEMBL6288766 0.75 LMNA (0.61) PDK2PDK4LMNAKMT2AMEN1
SCHEMBL29588465 0.75 LMNA (0.61) PDK2PDK4LMNAKMT2AMEN1
SCHEMBL31076274 0.74 MAPT (0.49) PDK2PDK4LMNAKMT2AMEN1
SCHEMBL25467800 0.74 GSK3B (0.50) PDK2PDK4LMNAALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3768664-B1 PYRAZINONE DERIVATIVES AS SHP2 INHIBITORS AND USES THEREOF SUZHOU PUHE BIOPHARMA CO LTD (CN) 2024-09-04 — — EP claimed
CN-117651707-A Novel synthetic TLR4 receptor agonists 米兰-比可卡大学 2024-03-05 — — CN claimed
EP-3833438-B1 SUBSTITUTED BENZIMIDAZOLES AS PAD4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2024-02-07 — — EP claimed
CN-105367481-A Synthetic method for 3,3-difluoro-2-oxindole derivative HENAN INST ENGINEERING 2016-03-02 — — CN claimed
EP-4747235-A1 KV1.3 POTASSIUM CHANNEL ANTAGONISTS Muna Therapeutics ApS (DK) 2026-05-27 — — EP disclosed
EP-4747234-A1 KV1.3 POTASSIUM CHANNEL ANTAGONISTS Muna Therapeutics ApS (DK) 2026-05-27 — — EP disclosed
US-12612424-B2 HPK1 inhibitors and uses thereof REGOR PHARMACEUTICALS, INC. (US) 2026-04-28 — — US disclosed
US-20250214942-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2025-07-03 — — US disclosed
US-12286406-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-04-29 — — US disclosed
US-20250092014-A1 COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE METREA BIOSCIENCES INC (US) 2025-03-20 — — US disclosed
US-20250051309-A1 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME GILEAD SCIENCES, INC. 2025-02-13 — — US disclosed
WO-2025017105-A1 KV1.3 POTASSIUM CHANNEL ANTAGONISTS MUNA THERAPEUTICS APS (DK) 2025-01-23 — — WO disclosed
CN-101421265-A Thiazole compounds as protein kinase b (pkb) inhibitors AMGEN INC (US) 2009-04-29 — — CN disclosed
EP-0921800-B1 SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES BRISTOL MYERS SQUIBB CO (US) 2004-04-14 — — EP disclosed
EP-0921800-A4 SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES BRISTOL MYERS SQUIBB CO (US) 2000-12-06 — — EP disclosed
US-6034266-A ANTIINFLAMMTORY AGENTS, ANALGESICS, ANTIARTHRITIC AGENTS FUNDACAO OSWALDO CRUZ-FIOCRUZ (BR) 2000-03-07 — — US disclosed
WO-1999058525-A1 INDOLE DERIVATIVES AS 5-HT2A LIGANDS AND AS SEROTONINE REUPTAKE INHIBITORS ELI LILLY AND COMPANY LIMITED (GB) 1999-11-18 — — WO disclosed
EP-0921800-A1 SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES BRISTOL-MYERS SQUIBB COMPANY (US) 1999-06-16 — — EP disclosed
US-5846990-A Substituted biphenyl isoxazole sulfonamides BRISTOL-MYERS SQUIBB CO. (US) 1998-12-08 — — US disclosed
WO-1997029748-A1 SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES BRISTOL-MYERS SQUIBB COMPANY (US) 1997-08-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612424-B2 HPK1 inhibitors and uses thereof NEK11, NEK1, CSNK1A1 PDK2 372/4885PDK4 477/4885LMNA 1648/4885
US-20250214942-A1 INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE RIPK1, RIPK2, RIPK4 PDK2 1164/4885PDK4 1543/4885LMNA 3119/4885
US-12286406-B2 Inhibitors of receptor interacting protein kinase I for the treatment of disease RIPK1, RIPK2, RIPK4 PDK2 1164/4885PDK4 1543/4885LMNA 3119/4885
US-20250051309-A1 MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME DUSP2, MKNK2, DUSP22 PDK2 139/4885PDK4 681/4885LMNA 4267/4885
US-20250092014-A1 COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE LPL, LIPA, PNLIP PDK2 1106/4885PDK4 971/4885LMNA 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.